Literature DB >> 16716139

Leflunomide and warfarin interaction: case report and review of the literature.

Jennifer Chonlahan1, Mary Ann Halloran, Amy Hammonds.   

Abstract

A 61-year-old Caucasian woman receiving long-term anticoagulation with warfarin for recurrent thromboembolism and atrial fibrillation was found to have an elevated international normalized ratio (INR) after she started leflunomide therapy for rheumatoid arthritis. Her INR had been stable for 4 months before this event. The patient required an overall decrease of 22% in her weekly warfarin dose to maintain a therapeutic INR within the goal range of 2.0-3.0 after adding leflunomide therapy. A comprehensive PubMed/MEDLINE search was conducted to identify literature addressing the potential interaction between warfarin and leflunomide. Evidence describing the interaction and its potential mechanism was limited to one published case report and to in vitro data, respectively. Our case report provides additional support that such an interaction exists and that it was at least partly responsible for the subsequent increase in the patient's INR. Therefore, continued evaluation and documentation of this potential drug interaction is imperative. To reduce the risk of adverse effects related to excessive anticoagulation with the start of leflunomide in patients taking warfarin, clinicians should increase their frequency of INR monitoring and adjust the warfarin dosage accordingly to maintain therapeutic anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16716139     DOI: 10.1592/phco.26.6.868

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s.

Authors:  Zhong-Hua Chen; Su-Xing Zhang; Na Long; Li-Shan Lin; Tao Chen; Fei-Peng Zhang; Xue-Qin Lv; Pei-Zhen Ye; Ning Li; Ke-Zhi Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-04-11       Impact factor: 6.150

2.  Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.

Authors:  Petra Bohanec Grabar; Blaz Rozman; Matija Tomsic; Dasa Suput; Dusan Logar; Vita Dolzan
Journal:  Eur J Clin Pharmacol       Date:  2008-05-22       Impact factor: 2.953

3.  Comments to prediction of advanced fibrosis in nonalcoholic fatty liver disease: an enhanced model of BARD score.

Authors:  Yong-Song Guan
Journal:  Gut Liver       Date:  2014-03-11       Impact factor: 4.519

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.